Kiniksa Pharmaceuticals International, plc (KNSA) Cash Flow Statement

The persistent gap between operating cash flow and net income, which turned positive in 2025Q1, suggests that reported earnings understate the company's cash-generating ability. The inclusion of non-cash charges like SBC and D&A, coupled with favorable working capital swings, has driven OCF/NI ratios above 2.0 in several quarters. This pattern implies that the company's profitability is not only real but also increasingly cash-backed, a positive signal for investors.

The trajectory of free cash flow shows a clear inflection point starting in 2025Q1, coinciding with the company's transition to profitability. FCF margins have consistently improved, reaching 26.4% in 2025Q4, and remain robust at 19.2% in 2026Q2. This trend suggests that the commercial scaling of ARCALYST is translating into substantial cash generation, which could support future investments or shareholder returns.

The company's capital expenditure is negligible, with quarterly CapEx never exceeding $0.7M, reflecting a business model that relies on outsourced manufacturing and a lean fixed-asset base. This low capital intensity allows nearly all operating cash flow to convert to free cash flow, a key differentiator versus traditional pharmaceutical manufacturers. The minimal capex suggests that future growth will not require significant capital outlays, preserving cash for pipeline development or strategic initiatives.

The working capital line has been a significant source of volatility, with positive contributions in some quarters (e.g., $20.5M in 2024Q4) and negative in others. This pattern likely reflects the timing of collections and payables, as well as inventory management, but does not appear to signal a structural deterioration. Investors should monitor the cash conversion cycle, as the company's ability to manage working capital efficiently will be key to sustaining high OCF/NI ratios.

The company has not initiated a dividend and has only engaged in token share repurchases, suggesting a deliberate strategy to reinvest cash into the business. This is consistent with the need to fund KPL-404 development and potentially expand ARCALYST's indications. The lack of significant capital returns implies that management sees higher-value opportunities internally, which could drive long-term shareholder value if successful.

The cumulative gap between operating cash flow and net income is substantial, with OCF totaling over four times net income. This divergence is largely attributable to non-cash charges like stock-based compensation and depreciation, as well as favorable working capital movements. The data suggests that the company's cash-generating ability is stronger than its reported profitability, which may not be fully reflected in valuation multiples.